Literature DB >> 25360222

Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma.

Angela J Yoon1, Shuang Wang2, Jing Shen3, Nicolas Robine4, Elizabeth Philipone1, Martin W Oster5, Albert Nam6, Regina M Santella3.   

Abstract

MicroRNAs (miRs) control cell growth, apoptosis and differentiation, and thus play a key role in carcinogenesis. Identification of a set of miRs that demonstrate differential expression in oral squamous cell carcinoma (OSCC) patients with poor prognosis has potential for utility as a prognostic marker. A retrospective study of miR expression was conducted in 20 tissue samples from early stage (Stages I & II) OSCC patients with known clinical outcome (10 from those who had 5-year disease free survival and 10 who died of disease within 5 years) using genome-wide deep sequencing analysis. The promising miR candidates were then validated in 80 tissue samples using quantitative real-time PCR (qRT-PCR). The deep sequencing and qRT-PCR analysis identified two promising miRs, miR-375 and miR-214-3p. Combining the two miRs as a panel with age and gender had a predictive value for the area under the curve (AUC) of 0.932, with a sensitivity of 87.5% and a specificity of 87.2% (p<0.0001) to identify patients with poor prognosis. A miR-based prognostic risk score model was constructed, which included the miR-214-3p, miR-375, age and gender, each weighed by relative contribution. The risk score model was able to identify high-risk individuals who had significantly shorter time to relapse (p<0.001) and time to death (p<0.001). The model consisting of a two-miR panel with age and gender may be useful in prognostication of early stage OSCC patients, which can aid in identifying patients with poor prognosis who will benefit from a subsequent aggressive treatment regimen.

Entities:  

Keywords:  deep sequencing; microRNA; oral squamous cell carcinoma; prognosis; qRT-PCR; risk score

Year:  2014        PMID: 25360222      PMCID: PMC4212932     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  47 in total

1.  Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.

Authors:  Na Liu; Nian-Yong Chen; Rui-Xue Cui; Wen-Fei Li; Yan Li; Rong-Rong Wei; Mei-Yin Zhang; Ying Sun; Bi-Jun Huang; Mo Chen; Qing-Mei He; Ning Jiang; Lei Chen; William C S Cho; Jing-Ping Yun; Jing Zeng; Li-Zhi Liu; Li Li; Ying Guo; Hui-Yun Wang; Jun Ma
Journal:  Lancet Oncol       Date:  2012-05-03       Impact factor: 41.316

Review 2.  Current potential and limitations of molecular diagnostic methods in head and neck cancer.

Authors:  Magdy E Mahfouz; Juan P Rodrigo; Robert P Takes; Mohamed N Elsheikh; Alessandra Rinaldo; Ruud H Brakenhoff; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06       Impact factor: 2.503

3.  Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

Authors:  Fabrice André; Thomas Bachelot; Mario Campone; Florence Dalenc; Jose M Perez-Garcia; Sara A Hurvitz; Nicholas Turner; Hope Rugo; John W Smith; Stephanie Deudon; Michael Shi; Yong Zhang; Andrea Kay; Diana Graus Porta; Alejandro Yovine; José Baselga
Journal:  Clin Cancer Res       Date:  2013-05-08       Impact factor: 12.531

4.  MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines.

Authors:  Zhi-wei Yu; Lai-ping Zhong; Tong Ji; Ping Zhang; Wan-tao Chen; Chen-ping Zhang
Journal:  Oral Oncol       Date:  2010-03-09       Impact factor: 5.337

5.  MicroRNA expression in head and neck cancer associates with alcohol consumption and survival.

Authors:  Michele Avissar; Michael D McClean; Karl T Kelsey; Carmen J Marsit
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

6.  Oral cavity and pharynx-throat cancer in the United States, 1973-2003.

Authors:  Brad Rodu; Philip Cole
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2007-07-25

7.  MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.

Authors:  Jinsong Li; Hongzhang Huang; Lijuan Sun; Mei Yang; Chaobin Pan; Weiliang Chen; Donghui Wu; Zhaoyu Lin; Chunxian Zeng; Yandan Yao; Peter Zhang; Erwei Song
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

8.  Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

Authors:  Hye Ryun Kim; Dae Joon Kim; Dae Ryong Kang; Jin Gu Lee; Sun Min Lim; Chang Young Lee; Sun Young Rha; Mi Kyung Bae; Young Joo Lee; Se Hoon Kim; Sang-Jun Ha; Ross Andrew Soo; Kyung Young Chung; Joo Hang Kim; Ji Hyun Lee; Hyo Sup Shim; Byoung Chul Cho
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

9.  SeqBuster, a bioinformatic tool for the processing and analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic cells.

Authors:  Lorena Pantano; Xavier Estivill; Eulàlia Martí
Journal:  Nucleic Acids Res       Date:  2009-12-11       Impact factor: 16.971

Review 10.  MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas.

Authors:  Dan Chen; Robert J Cabay; Yi Jin; Anxun Wang; Yang Lu; Muzaffar Shah-Khan; Xiaofeng Zhou
Journal:  J Oral Maxillofac Res       Date:  2013-04-01
View more
  13 in total

1.  Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway.

Authors:  Xiangjun Chen; Hao Dong; Sha Liu; Li Yu; Dexiong Yan; Xingwei Yao; Weijing Sun; Dezhi Han; Guozhen Gao
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

2.  MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.

Authors:  Zhi-cai Shi; Xue-rong Chu; Yun-gang Wu; Jin-hui Wu; Chun-wen Lu; Run-xiao Lü; Mu-chen Ding; Ning-fang Mao
Journal:  Tumour Biol       Date:  2015-06-03

3.  Targeting miR-21 with AS-miR-21 suppresses aggressive growth of human tongue squamous cell carcinoma in vivo.

Authors:  Yin Wang; Yu Zhu; Pin Lv; Longjiang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  The role of miR-21 in proliferation and invasion capacity of human tongue squamous cell carcinoma in vitro.

Authors:  Yin Wang; Yu Zhu; Pin Lv; Longjiang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1.

Authors:  Chibo Liu; Jianjun Lin
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

6.  Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma.

Authors:  Huanxi Xu; Yuqi Yang; Hongmei Zhao; Xuguang Yang; Yu Luo; Yinxiang Ren; Wei Liu; Ning Li
Journal:  Tumour Biol       Date:  2015-07-30

7.  MicroRNAs-208b-3p, 204-5p, 129-2-3p and 3065-5p as predictive markers of oral leukoplakia that progress to cancer.

Authors:  Elizabeth Philipone; Angela J Yoon; Shuang Wang; Jing Shen; Yen Chen Kevin Ko; Jill M Sink; Andrew Rockafellow; Nathanel A Shammay; Regina M Santella
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

8.  MicroRNA-196a-5p is a potential prognostic marker of delayed lymph node metastasis in early-stage tongue squamous cell carcinoma.

Authors:  Tessho Maruyama; Kazuhide Nishihara; Masato Umikawa; Akira Arasaki; Toshiyuki Nakasone; Fumikazu Nimura; Akira Matayoshi; Kimiko Takei; Saori Nakachi; Ken-Ichi Kariya; Naoki Yoshimi
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

9.  Long noncoding RNA ILF3-AS1 promotes cell proliferation, migration, and invasion via negatively regulating miR-200b/a/429 in melanoma.

Authors:  Xiangjun Chen; Sha Liu; Xiaochun Zhao; Xiao Ma; Guozhen Gao; Li Yu; Dexiong Yan; Hao Dong; Weijing Sun
Journal:  Biosci Rep       Date:  2017-11-06       Impact factor: 3.840

10.  MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion.

Authors:  Yadong Wu; Xiangjie Sun; Bin Song; Xiaoling Qiu; Jianjiang Zhao
Journal:  Cancer Med       Date:  2017-06-19       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.